CD8A and neoplasm: The high frequency of tumor-infiltrating T cells (revealed by immunostaining of CD8) and the high frequency of PD-1 expression in tumor-infiltrating lymphocytes in the current cases of RSEAC suggest that immune checkpoint inhibitor therapy could also be effective for patients with RSEAC.